Biome Australia Limited (BIO.AX)
AUD 0.44
(1.15%)
AUD 0.44
(1.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.67 Million AUD | 45.75% |
| 2023 | -3.07 Million AUD | 32.2% |
| 2022 | -4.54 Million AUD | 15.62% |
| 2021 | -5.38 Million AUD | -70.17% |
| 2020 | -3.16 Million AUD | -57.17% |
| 2019 | -2.01 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.52 Million AUD | -100.0% |
| 2024 FY | -1.67 Million AUD | 45.75% |
| 2024 Q4 | -144.81 Thousand AUD | 0.0% |
| 2024 Q1 | -762.69 Thousand AUD | 43.07% |
| 2023 Q2 | -1.73 Million AUD | -100.0% |
| 2023 FY | -3.07 Million AUD | 32.2% |
| 2023 Q4 | -1.33 Million AUD | -100.0% |
| 2023 Q3 | -669.79 Thousand AUD | 61.48% |
| 2023 Q1 | -869.46 Thousand AUD | 57.81% |
| 2022 Q1 | -1.23 Million AUD | 40.0% |
| 2022 FY | -4.54 Million AUD | 15.62% |
| 2022 Q4 | -2.06 Million AUD | -100.0% |
| 2022 Q3 | -1.03 Million AUD | 58.45% |
| 2022 Q2 | -2.47 Million AUD | -100.0% |
| 2021 Q3 | -1.03 Million AUD | 68.83% |
| 2021 Q4 | -2.06 Million AUD | -100.0% |
| 2021 FY | -5.38 Million AUD | -70.17% |
| 2021 Q1 | -1.65 Million AUD | 0.0% |
| 2021 Q2 | -3.31 Million AUD | -100.0% |
| 2020 FY | -3.16 Million AUD | -57.17% |
| 2019 FY | -2.01 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 68.963% |
| Acrux Limited | -5.8 Million AUD | 71.203% |
| Actinogen Medical Limited | -13.04 Million AUD | 87.196% |
| AnteoTech Limited | -8.88 Million AUD | 81.193% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 69.519% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 80.903% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -15.088% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 91.266% |
| Amplia Therapeutics Limited | -4.5 Million AUD | 62.913% |
| Avecho Biotechnology Limited | -3.43 Million AUD | 51.399% |
| Bio-Gene Technology Limited | -2.4 Million AUD | 30.673% |
| Biotron Limited | -3.43 Million AUD | 51.399% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 87.958% |
| BTC Health Limited | 1.05 Million AUD | 258.27% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 86.67% |
| CSL Limited | 2.64 Billion AUD | 100.063% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 96.054% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 104.687% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 82.86% |
| Dimerix Limited | -17.07 Million AUD | 90.218% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 123.982% |
| Hexima Limited | -933.87 Thousand AUD | -78.847% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | 41.689% |
| Immuron Limited | -6.93 Million AUD | 75.923% |
| Immutep Limited | -39.89 Million AUD | 95.814% |
| Imugene Limited | -149.68 Million AUD | 98.884% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -1.729% |
| Memphasys Limited | -4.44 Million AUD | 62.4% |
| Nanollose Limited | -1.15 Million AUD | -44.412% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 101.063% |
| Noxopharm Limited | -3.57 Million AUD | 53.322% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 615.161% |
| Nyrada Inc. | -1.38 Million AUD | -20.485% |
| Orthocell Limited | -7.18 Million AUD | 76.741% |
| PharmAust Limited | -9.03 Million AUD | 81.509% |
| Patrys Limited | -3.53 Million AUD | 52.808% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 97.152% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 73.806% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 79.726% |
| PYC Therapeutics Limited | -37.72 Million AUD | 95.573% |
| Race Oncology Limited | -13.81 Million AUD | 87.914% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 96.517% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 90.543% |
| Starpharma Holdings Limited | -8.16 Million AUD | 79.544% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 132.051% |
| Tissue Repair Ltd | -4.13 Million AUD | 59.638% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 95.433% |